Vesting condition for the incentive have been met. A well deserved reward for the Neuren employees if you ask me
from the annoucment dated 03/02/2022
Material terms:- Exercise price ($3.46 per share) is the volume weighted average price (VWAP) at which the Company's shares weretraded on the ASX in the 5 days preceding the date of issue of the Options.
- Vested options may be exercised no earlier than 1 year after the issue date.
- All options lapse 4 years after the issue date.
- Options are subject to the following vesting conditions:
(a) when the Company determines to progress NNZ-2591 to a Phase 2b or Phase 3 clinical trial following a positive Phase2 clinical trial outcome, or executes a partnering transaction for NNZ-2591;
(b) when the Company executes a partnering transaction for trofinetide outside North America, or submits a MarketingAuthorisation Application for trofinetide in the European Union, the United Kingdom or Japan.
(c) on acceptance by the US FDA of the filing of a New Drug Application for trofinetide.- The options carry no entitlement to vote or participate in new issues.
- Forums
- ASX - By Stock
- Ann: Application for quotation of securities - NEU
Vesting condition for the incentive have been met. A well...
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.35 |
Change
0.520(3.76%) |
Mkt cap ! $1.834B |
Open | High | Low | Value | Volume |
$13.96 | $14.35 | $13.66 | $6.469M | 457.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 2023 | $14.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.38 | 1777 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 2023 | 14.270 |
1 | 1777 | 14.250 |
1 | 105 | 14.240 |
2 | 5645 | 14.230 |
1 | 1594 | 14.210 |
Price($) | Vol. | No. |
---|---|---|
14.380 | 1777 | 1 |
14.400 | 1523 | 2 |
14.410 | 1777 | 1 |
14.430 | 1777 | 1 |
14.450 | 1250 | 1 |
Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |